Division of Johnson & Johnson
Latest From Axovan AG
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
Acquiring compatriot Axovan was Actelion's only option to access Phase II endothelin receptor antagonist (ERA) clazosentan; a licensing deal would have left Axovan with too little to remain a standalone company. But the CHF 252 million ($191 million) deal still makes sense for Actelion: the company's initial financial exposure is just CHF 40 million, with most of the remaining deal value linked to milestones. Actelion gains access to a late-stage compound it knows well, that fits perfectly within its own ERA-focused portfolio. Furthermore, it beefs up its R&D and bolsters its preclinical pipeline, all for little more than it would have had to pay for clazosentan alone. Axovan puts its lead compound in the hands of a partner with a proven track record in ERA development and commercialization.
Summarizing the month in European dealmaking.
Founded in June 2000 by two professors from Sweden's Karolinska Institute, Biolipox AB is focusing on the role of arachidonic acid in inflammation, and looking to develop an improved family of respiratory and anti-inflammatory drugs.
- Therapeutic Areas
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
- Philippe Dro, MD, CEO
- Contact Info
Phone: (41) 61 487 76 76
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.